Savara

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The firm's lead program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Austin, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the third quarter ending September 30, 2020 and provided a business update. “After recently joining the management team, it's clear that we must focus on three priorities in the near-term,” said Matthew Pauls, Chairman and Interim CEO, Savara. “The first is advancing our lead program, Molgradex in aPAP and the Phase 3 IMPALA 2 trial, as quickly and as safely as we can

Savara Reports Third Quarter 2020 Financial Results and Provides Business Update

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Rob Neville has resigned as the Company’s Chief Executive Officer (CEO) and from the Board of Directors, effective immediately, to pursue other opportunities.

Savara Announces Senior Management Changes

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the H.C.

Savara to Present at the 22nd Annual H.C. Wainwright Annual Investment Conference Being Held Virtually

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that results from the Phase 3 IMPALA study were published online in NEJM.

Savara Announces New England Journal of Medicine (NEJM) Publication of IMPALA Study Results

Savara (SVRA) to halt the ENCORE study on its lead candidate Molgradex, which was meant to treat nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis.

Savara to Stop Study on Molgradex for NTM Lung Infection

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the decision to discontinue ENCORE, a 48-week, open-label, non-controlled Phase 2a exploratory clinical study of Molgradex for the treatment of nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis (CF).

Savara to Discontinue Exploratory ENCORE Study Evaluating Molgradex for the Treatment of NTM Lung Infection in People Living With Cystic Fibrosis (CF)

Savara has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Savara Enters Oversold Territory

Savara Inc (SVRA) CEO Robert Neville on Q2 2020 Results - Earnings Call Transcript

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the second quarter ending June 30, 2020 and provided a business update.

Savara Reports Second Quarter 2020 Financial Results and Provides Business Update

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the virtual Canaccord Genuity Global Growth Conference on Wednesday, August 12, 2020 at 8:00 a.m.

Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report second quarter 2020 financial results and provide a business update on Thursday, August 6, 2020.

Savara to Report Second Quarter 2020 Financial Results and Provide Business Update

Blink Charging

Liquidia Technologies Inc

Navidea Biopharma

Many believe that the market does not accurately the current state of our economy. With double-digit unemployment and Q2 earnings expected to disappoint, the stock market is rich with several Top Shorts for you to hedge out or bet with your portfolio today.

Top Stocks To Short With VIX Rallying

Savara Inc. (SVRA) CEO Rob Neville on Q1 2020 Results - Earnings Call Transcript

Savara has been struggling lately, but the selling pressure may be coming to an end soon.

Savara Sees Hammer Chart Pattern: Time to Buy?

Savara Inc. (SVRA) CEO Rob Neville on Q4 2019 Results - Earnings Call Transcript

Savara (SVRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Savara (SVRA) This Earnings Season?

Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Savara (SVRA) Stock?

Savara Inc. (NASDAQ: SVRA) shares more than doubled on Monday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for its autoimmune pulmonary alveolar proteinosis (aPAP) treatment Molgradex.

Why This aPAP Treatment Is a Big Hit

Intelsat

These companies have a low financial burden.

2 Falling Knives for Investors to Consider

Shares of Savara Inc. SVRA, -6.42% tumbled 48% in premarket trade Wednesday, after the orphan lung disease company said the U.S.

Savara shares slide 48% premarket after FDA rejects lung-disease treatment Molgradex

Savara Inc. (SVRA) CEO Rob Neville on Q2 2019 Results - Earnings Call Transcript

Abeona Therapeutics

Allergan

Alexion Pharma

Amgen

Regeneron Pharmaceuticals

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data

Cooper-Standard Holdings

HEXO Corp

A host of factors pulled some stocks down.

Why HEXO, Savara, and Cooper-Standard Holdings Slumped Today

Investors just received some bad news about the company's lead drug candidate.

Here's Why Savara Pharmaceuticals Collapsed Today

Shares of the thinly traded small-cap biotech Savara Inc (NASDAQ: SVRA) were plunging to a record low Thursday in the wake of a clinical trial readout from the company.

News for Savara Stock (SVRA)